TDC
SRPT icon

Thompson Davis & Co’s Sarepta Therapeutics SRPT Stock Holding History

Thompson Davis & Co’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$13K Buy
80
+30
+60% +$4.1K 0.03% 416
2018
Q2 		$7K Buy
+50
New +$4.71K 0.02% 481
2017
Q3 		– Sell
-200
Closed -$7K – 1192
2017
Q2 		$7K Buy
+200
New +$6.51K 0.01% 764
2016
Q1 		– Sell
-125
Closed -$5K – 1158
2015
Q4 		$5K Hold
125
– – 0.01% 836
2015
Q3 		$4K Buy
+125
New +$4.24K 0.01% 895

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Thompson Davis & Co's SRPT Position: Q3 2018 in Review

Thompson Davis & Co increased its Sarepta Therapeutics (SRPT) stake by 60% in Q3 2018, buying an estimated $4.1K and bringing the position to 80 shares worth $13K. The position accounts for 0.03% of the portfolio, ranked #416.

Thompson Davis & Co first reported a position in SRPT in Q3 2015 and has held it in 5 quarters since. 344 funds tracked by Wall St. Rank hold SRPT as of Q3 2018.

  • Thompson Davis & Co held 80 shares of Sarepta Therapeutics worth $13K as of Q3 2018.
  • Thompson Davis & Co bought 30 Sarepta Therapeutics shares in Q3 2018, an estimated $4.1K.
  • Sarepta Therapeutics made up 0.03% of Thompson Davis & Co's portfolio in Q3 2018, its #416 holding.
  • Thompson Davis & Co first reported a position in Sarepta Therapeutics in Q3 2015 and has held it in 5 quarters since.
  • 344 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2018.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.